Padsevonil

Padsevonil

Clinical data
Other names	UCB-0942; UCB0942; UCB1415943-000
Routes of administration	Oral[1]
Drug class	Synaptic vesicle glycoprotein 2A (SV2A) ligand[2]
Identifiers
IUPAC name (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one
CAS Number	1294000-61-5
PubChem CID	52911611
DrugBank	DB14977
ChemSpider	58828036
UNII	0R1HN52K0N
KEGG	D11842
ChEMBL	ChEMBL4297521
Chemical and physical data
Formula	C14H14ClF5N4O2S
Molar mass	432.79 g·mol−1
3D model (JSmol)	Interactive image
SMILES COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl
InChI InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1 Key:DCXFIOLWWRXEQH-SSDOTTSWSA-N

Padsevonil (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, JANTooltip Japanese Accepted Name; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy.^[1][3][2] It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam.^[2] However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam.^[2] In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B (SV2B) and 2C (SV2C).^[2] The drug is being developed by UCB.^[1][3] As of November 2023, it is in phase 2 clinical trials.^[1][3]